Studies how Selank and its minimal active fragment Gly-Pro alter cytokine and chemokine gene expression in mouse spleen. Both Selank and Gly-Pro produced similar changes in gene expression 6 and 24 hours after injection—including genes for interferons, interleukins, and their receptors. Identifies Gly-Pro as the pharmacophore responsible for Selank's immunomodulatory antiviral effects.
Kolomin, T A; Shadrina, M I; Slominskiĭ, P A; Limborskaia, S A; Miasoedov, N F